Lexaria Bioscience Corp. reported its full year 2024 financial results on November 28, 2024. The company announced a net loss of US$5.80 million for the fiscal year.
Despite the net loss, the company's financial performance indicates a narrowing of the loss compared to the prior year. This reflects ongoing investments in research and development activities.
The results highlight Lexaria's status as a development-stage biotechnology company, with continued capital requirements to fund its clinical programs and strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.